Association of serum neurofilament light with microglial activation in multiple sclerosis

被引:17
作者
Saraste, Maija [1 ,2 ,3 ]
Matilainen, Markus [1 ,4 ]
Vuorimaa, Anna [1 ,2 ,3 ]
Laaksonen, Sini [1 ,2 ,3 ]
Sucksdorff, Marcus [1 ,2 ,3 ]
Leppert, David [5 ,6 ,7 ,8 ,9 ]
Kuhle, Jens [5 ,6 ,7 ,8 ,9 ]
Airas, Laura [1 ,2 ,3 ]
机构
[1] Turku PET Ctr, Turku 20521, Finland
[2] Turku Univ Hosp, Neuroctr, Turku, Finland
[3] Univ Turku, Clin Neurosci, Turku, Finland
[4] Abo Akad Univ, Fac Sci & Engn, Turku, Finland
[5] Univ Hosp, Dept Neurol, Basel, Switzerland
[6] Univ Basel, Basel, Switzerland
[7] Univ Hosp, Multiple Sclerosis Ctr, Dept Biomed, Basel, Switzerland
[8] Univ Hosp, Multiple Sclerosis Ctr, Dept Clin Res, Basel, Switzerland
[9] Univ Hosp, Res Ctr Clin Neuroimmunol & Neurosci RC2NB, Basel, Switzerland
基金
芬兰科学院;
关键词
Multiple Sclerosis; PET; Microglia; TSPO; Neurofilament light; INFLAMMATION; BIOMARKER;
D O I
10.1136/jnnp-2023-331051
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundTranslocator protein (TSPO)-PET and neurofilament light (NfL) both report on brain pathology, but their potential association has not yet been studied in multiple sclerosis (MS) in vivo. We aimed to evaluate the association between serum NfL (sNfL) and TSPO-PET-measurable microglial activation in the brain of patients with MS. MethodsMicroglial activation was detected using PET and the TSPO-binding radioligand [C-11]PK11195. Distribution volume ratio (DVR) was used to evaluate specific [C-11]PK11195-binding. sNfL levels were measured using single molecule array (Simoa). The associations between [C-11]PK11195 DVR and sNfL were evaluated using correlation analyses and false discovery rate (FDR) corrected linear regression modelling. Results44 patients with MS (40 relapsing-remitting and 4 secondary progressive) and 24 age-matched and sex-matched healthy controls were included. In the patient group with elevated brain [C-11]PK11195 DVR (n=19), increased sNfL associated with higher DVR in the lesion rim (estimate (95% CI) 0.49 (0.15 to 0.83), p(FDR)=0.04) and perilesional normal appearing white matter (0.48 (0.14 to 0.83), p(FDR)=0.04), and with a higher number and larger volume of TSPO-PET-detectable rim-active lesions defined by microglial activation at the plaque edge (0.46 (0.10 to 0.81), p(FDR)=0.04 and 0.50 (0.17 to 0.84), p(FDR)=0.04, respectively). Based on the multivariate stepwise linear regression model, the volume of rim-active lesions was the most relevant factor affecting sNfL. ConclusionsOur demonstration of an association between microglial activation as measured by increased TSPO-PET signal, and elevated sNfL emphasises the significance of smouldering inflammation for progression-promoting pathology in MS and highlights the role of rim-active lesions in promoting neuroaxonal damage.
引用
收藏
页码:698 / 706
页数:9
相关论文
共 50 条
[21]   Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis [J].
Amor, Sandra ;
van der Star, Baukje J. ;
Bosca, Isabel ;
Raffel, Joel ;
Gnanapavan, Sharmilee ;
Watchorn, Jonathan ;
Kuhle, Jens ;
Giovannoni, Gavin ;
Baker, David ;
Malaspina, Andrea ;
Puentes, Fabiola .
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (10) :1355-1362
[22]   Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives [J].
Jakimovski, Dejan ;
Dwyer, Michael G. ;
Bergsland, Niels ;
Weinstock-Guttman, Bianca ;
Zivadinov, Robert .
NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (04) :329-340
[23]   Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis [J].
Sucksdorff, Marcus ;
Rissanen, Eero ;
Tuisku, Jouni ;
Nuutinen, Salla ;
Paavilainen, Teemu ;
Rokka, Johanna ;
Rinne, Juha ;
Airas, Laura .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (10) :1646-1651
[24]   Association between serum neurofilament light chain and periodontitis [J].
Zhao, Jing ;
Zhao, Panwen .
CLINICAL ORAL INVESTIGATIONS, 2024, 28 (07)
[25]   The potential of serum neurofilament as biomarker for multiple sclerosis [J].
Bittner, Stefan ;
Oh, Jiwon ;
Havrdova, Eva Kubala ;
Tintore, Mar ;
Zipp, Frauke .
BRAIN, 2021, 144 :2954-2963
[26]   High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis [J].
Buchmann, Arabella ;
Pirpamer, Lukas ;
Pinter, Daniela ;
Voortman, Margarete ;
Helmlinger, Birgit ;
Pichler, Alexander ;
Maceski, Aleksandra Maleska ;
Benkert, Pascal ;
Bachmaier, Gerhard ;
Ropele, Stefan ;
Reindl, Markus ;
Leppert, David ;
Kuhle, Jens ;
Enzinger, Christian ;
Khalil, Michael .
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (05) :1389-1399
[27]   Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode [J].
Plavina, Tatiana ;
Singh, Carol M. ;
Sangurdekar, Dipen ;
de Moor, Carl ;
Engle, Bob ;
Gafson, Arie ;
Goyal, Jaya ;
Fisher, Elizabeth ;
Szak, Suzanne ;
Kinkel, Revere P. ;
Sandrock, Alfred W. ;
Su, Ray ;
Kieseier, Bernd C. ;
Rudick, Richard A. .
JAMA NETWORK OPEN, 2020, 3 (11)
[28]   Vitamin D supplementation and neurofilament light chain in multiple sclerosis [J].
Holmoy, Trygve ;
Rosjo, Egil ;
Zetterberg, Henrik ;
Blennow, Kaj ;
Lindstrom, Jonas Christoffer ;
Steffensen, Linn Hofsoy ;
Kampman, Margitta T. .
ACTA NEUROLOGICA SCANDINAVICA, 2019, 139 (02) :172-176
[29]   Kynurenines and Neurofilament Light Chain in Multiple Sclerosis [J].
Pukoli, Daniel ;
Polyak, Helga ;
Rajda, Cecilia ;
Vecsei, Laszlo .
FRONTIERS IN NEUROSCIENCE, 2021, 15
[30]   Neurofilament Light Chain as a Biomarker in Multiple Sclerosis [J].
Varhaug, Kristin N. ;
Torkildsen, Oivind ;
Myhr, Kjell-Morten ;
Vedeler, Christian A. .
FRONTIERS IN NEUROLOGY, 2019, 10